Want to see VBIO full AI Analyst Report?
Top Page
Valion Bio
(NASDAQ:VBIO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.50
▲(2087.50% Upside)
Action:Reiterated
Date:09/25/26
The score is held down primarily by weak financial quality (large ongoing losses and cash burn) and bearish technical signals (price below key moving averages with negative MACD). A low-debt balance sheet and several positive corporate updates provide partial support, but valuation remains constrained by loss-making results and the potential reverse split/financing terms add risk.
Positive Factors
Low leverage and capital base
Very low debt relative to equity gives Valion Bio greater financial flexibility than a highly leveraged biotech and reduces immediate interest and refinancing pressure. Its asset base provides some support for continued development, although persistent losses could erode equity over time.
Negative Factors
Severe operating losses
Operating costs currently dwarf the revenue base, leaving Valion Bio far from sustainable profitability. Such severe losses can consume equity, increase dependence on external capital, and make future growth less valuable unless revenue expands substantially or the cost structure improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and capital base
Very low debt relative to equity gives Valion Bio greater financial flexibility than a highly leveraged biotech and reduces immediate interest and refinancing pressure. Its asset base provides some support for continued development, although persistent losses could erode equity over time.
Read all positive factors
Valion Bio (VBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.09M
Dividend YieldN/A
Average Volume (3M)700.89K
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue Growth-49.63%
EPS Growth82.22%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-56.74
Shares Outstanding887,590
10 Day Avg. Volume359,247
30 Day Avg. Volume700,887
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.49
Price to Sales (P/S)0.00
P/FCF Ratio-5.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valion Bio Business Overview & Revenue Model
Company Description
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat...
Valion Bio Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 13, 2026
Earnings Call Sentiment Neutral
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.Positive Updates
Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Negative Updates
Increased Net Loss
Net loss for Q3 2025 was $2.6 million compared to $1.4 million in Q3 2024.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Read all positive updates
Company Guidance
During the third quarter of 2025, Tivic Health Systems reported significant progress in its strategic transformation towards the biopharmaceutical market, having licensed entolimod and related assets to pivot from bioelectronics to biologic pharmaceuticals. The company is focusing on entolimod as a military countermeasure for acute radiation syndrome (ARS) and has moved forward with transferring two INDs related to ARS and advanced cancer. Financially, Tivic saw revenue net of returns at $140,000 for the quarter, an increase from $126,000 in the previous year, although nine-month revenue decreased to $302,000 from $600,000 due to reduced advertising spend. The cost of sales rose to $291,000, influenced by a $230,000 inventory reserve, while gross margins excluding this reserve improved to 42% from 35%. Operating expenses increased to $2,300,000 from $1,500,000 due to heightened R&D investments and corporate costs. The net loss widened to $2,600,000 from $1,400,000, and cash reserves grew to $3,500,000, supported by additional financing tranches totaling $3,800,000 during the quarter.Valion Bio Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
70
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2024 | Dec 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -156.00K | 0.00 | 0.00 | 1.18M | 1.84M | 1.26M |
| Gross Profit | -805.00K | 0.00 | -352.00K | 287.00K | 299.00K | -46.00K |
| EBITDA | -15.87M | -7.84M | -4.06M | -8.06M | -9.92M | -5.61M |
| Net Income | -18.75M | -8.88M | -5.66M | -8.24M | -10.10M | -8.49M |
Balance Sheet | ||||||
| Total Assets | 32.47M | 31.61M | 2.81M | 5.16M | 5.88M | 15.04M |
| Cash, Cash Equivalents and Short-Term Investments | 2.11M | 12.64M | 2.00M | 3.40M | 3.52M | 12.97M |
| Total Debt | 17.41M | 6.45M | 0.00 | 369.00K | 530.00K | 708.00K |
| Total Liabilities | 20.59M | 14.81M | 272.00K | 1.58M | 2.25M | 1.76M |
| Stockholders Equity | 11.88M | 16.80M | 2.54M | 3.58M | 3.63M | 13.27M |
Cash Flow | ||||||
| Free Cash Flow | -14.67M | -7.04M | -5.72M | -8.63M | -8.93M | -5.61M |
| Operating Cash Flow | -14.57M | -7.00M | -5.72M | -8.51M | -8.92M | -5.61M |
| Investing Cash Flow | -223.00K | -705.00K | 0.00 | -118.00K | -11.00K | 0.00 |
| Financing Cash Flow | 16.09M | 18.35M | 4.33M | 8.51M | -528.00K | 17.54M |
Valion Bio Technical Analysis
Neutral
0.16
Price Trends
4.98
Negative
11.39
Negative
20.51
Negative
Market Momentum
-0.70
Negative
50.69
Neutral
65.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VBIO, the sentiment is Neutral. The current price of 0.16 is below the 20-day moving average (MA) of 2.62, below the 50-day MA of 4.98, and below the 200-day MA of 20.51, indicating a neutral trend. The MACD of -0.70 indicates Negative momentum. The RSI at 50.69 is Neutral, neither overbought nor oversold. The STOCH value of 65.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VBIO.
Valion Bio Risk Analysis
Valion Bio disclosed 60 risk factors in its most recent earnings report. Valion Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Valion Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $3.09M | -0.05 | -165.44% | ― | -49.63% | 82.22% | |
48 Neutral | $10.86M | -0.54 | -123.09% | ― | ― | 87.54% | |
48 Neutral | $378.00M | -0.96 | -9.67% | ― | 843.62% | 21.98% | |
44 Neutral | $4.24M | -0.08 | -125.01% | ― | ― | 93.91% | |
43 Neutral | $2.94M | >-0.01 | -605.75% | ― | 8.36% | 88.88% |
* Healthcare Sector Average
VBIO
Valion Bio
3.03
-70.97
-95.91%
NUWE
Nuwellis
0.78
-121.02
-99.36%
AEMD
Aethlon Medical
6.28
-31.34
-83.30%
BBLG
Bone Biologics
0.50
-1.90
-79.33%
MOVE
Corvex
11.77
7.69
188.34%
BJDX
Bluejay Diagnostics
0.92
-5.04
-84.55%
Valion Bio Corporate Events
Business Operations and StrategyExecutive/Board Changes
Valion Bio Names Interim CEO Amid Governance Reshuffle
Positive
Sep 23, 2026
On September 22, 2026, Valion Bio appointed board member and life sciences veteran Dean Zikria as Interim Chief Executive Officer, effective immediately, under a consulting agreement that treats him as an independent contractor and runs through Ja...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingStock Split
Valion Bio raises capital via new preferred financing
Neutral
Sep 1, 2026
On August 31, 2026, Valion Bio entered a letter agreement with investor 3i to issue additional Series B and Series C non-voting convertible preferred shares and accompanying warrants for an aggregate purchase price of about $7.7 million, adjusted ...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Valion Bio Enacts Reverse Stock Split to Maintain Listing
Neutral
Aug 27, 2026
Valion Bio, Inc., a Nasdaq-listed biotech focused on immune-modulating biologics for radiation-related and immune dysfunction conditions, is advancing lead drug Entolimod for Acute Radiation Syndrome under special FDA provisions, alongside next-ge...
Private Placements and FinancingShareholder MeetingsStock Split
Valion Bio Secures New Series B Preferred Financing
Positive
Aug 17, 2026
On August 17, 2026, Valion Bio entered into a letter agreement with 3i, LP to issue 1,500 shares of Series B Non-Voting Convertible Preferred Stock at $1,000 per share and associated Series B warrants for a total of $1.5 million, under a previousl...
Business Operations and StrategyPrivate Placements and Financing
Valion Bio Issues Milestone Preferred Stock to Investors
Positive
Aug 6, 2026
Valion Bio, a company engaged in the development and commercialization of licensed products, has advanced its commercialization efforts by validating its current inventory of materials for distribution and sales, marking a significant operational ...
Business Operations and StrategyProduct-Related Announcements
Valion Bio advances Entolimod platform and manufacturing scale-up
Positive
Jul 15, 2026
On July 14, 2026, Valion Bio reported a series of developments that mark its evolution from a single-product developer into a broader platform company. The update highlighted the Entolimod program’s positioning across government radiation pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.